Commentary: Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)
- PMID: 41473096
- PMCID: PMC12745645
- DOI: 10.3389/fvets.2025.1649240
Commentary: Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)
Keywords: canine osteoarthritis; disproportionality analysis; dogs; evidence-based medicine; osteoarthritis; pharmacovigilance; statistical accuracy.
Conflict of interest statement
The author declares that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
-
Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela).Front Vet Sci. 2025 May 9;12:1581490. doi: 10.3389/fvets.2025.1581490. eCollection 2025. Front Vet Sci. 2025. PMID: 40417367 Free PMC article.
References
-
- PARACETAMOL . Making Medicines and Medical Devices Safer. Available online at: https://yellowcard.mhra.gov.uk/idaps/PARACETAMOL (Accessed June 15, 2025).
-
- MELOXICAM . Making Medicines and Medical Devices Safer. Available online at: https://yellowcard.mhra.gov.uk/idaps/MELOXICAM (Accessed June 15, 2025).
-
- Food and Drug Administration . Standard Adverse Event Pharmacovigilance Review for Librela TM. Glasgow: Food and Drug Administration; (2024).
Publication types
LinkOut - more resources
Full Text Sources
